A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
AML, selinexor, sorafenib, FLT3-mutation
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Naval Daver, Rita Assi, Farhad Ravandi, Guillermo Garcia-Manero, Elias Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Jing Ning, Graciela Nogueras-Gonzalez, Sherry Pierce, Dan Gombos, Steven Kornblau, Marina Konopleva, Mary Kelly, Gautam Borthakur, Weiguo Source Type: research